CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit
Globe Newswire•28/09/2026•07:30 ET
0
New 50 mg tablet formulation delivers an improved pharmacokinetic profile and enables greater exposure and patient convenience
FDA removal of the prior drug exposure limit provides greater dosing flexibility in future clinical trials
Get started
Create a free account to read the full story and Whiz Insights.